CPAP for secondary cardiovascular prevention in obstructive sleep apnoea patients: not only one moon, but many stars

Sébastien Baillieul; Neeraj M. Shah; Rivindi Dharmasena; Sophia Schiza; Dries Testelmans; Athanasia Pataka

doi:10.1183/20734735.0148-2022

Tables

TABLE 1

General characteristics of the participants included in the randomised controlled trials assessing the effects of continuous positive airway pressure (CPAP) treatment on cardiovascular morbimortality

	SAVE study [12]	RICCADSA study [13]	ISAACC study [15]
Inclusion criteria	Moderate-severe OSA (ODI ≥12 events·h⁻¹)	Moderate-severe OSA (AHI ≥15 events·h⁻¹)	Moderate-severe OSA (AHI ≥15 events·h⁻¹)
	Coronary artery disease or cerebrovascular disease	Coronary artery disease	Acute coronary syndrome
Exclusion criteria	Severe daytime sleepiness (ESS >15/24)	Excessive daytime sleepiness (ESS ≥10/24)	Excessive daytime sleepiness (ESS >10/24)
Age, years	61	66	60
Men, %	81	85	84
ESS	7.4	5.5	5.2
AHI, events·h⁻¹	31	29	36
Number of events, n (%)	CPAP: 229 (17%)	CPAP: 22 (18%)	CPAP: 98 (16%)
	Usual care: 207 (15%)	Usual care: 27 (22%)	Usual care: 108 (17%)
CPAP use, mean±sd, h per night	3.3±2.3	Not stated	2.8±2.7

Age, ESS, AHI are presented as the mean values for the study cohort. AHI: apnoea–hypopnoea index; ESS: Epworth sleepiness scale; ODI: oxygen desaturation index; OSA: obstructive sleep apnoea.